Experts' mixed responses to the surprise announcement of psilocybin & MDMA becoming (limitedly) licensed in Australia

The Australian Therapeutic Goods Administration has announced that psilocybin for treatment-resistant depression and MDMA for PTSD will be legally prescribable from July by specialist psychiatrists, who have obtained approval to use psychedelics. This change also opened up the use for clinical trials with MDMA and psilocybin in Australia. In this helpful article, Paul Liknaitzky, who heads Australia's first clinical psychedelic lab, discusses some pros and cons of this move.

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

Therapeutic effect of psilocybin in addiction: A systematic review

Next
Next

Classic psychedelics do not affect T cell and monocyte immune responses